
Rigel Pharmaceuticals (NASDAQ:RIGL) brought in sales totaling $20.41 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 8.06%, resulting in a loss of $22.64 million. Rigel Pharmaceuticals collected $21.54 million in revenue during Q3, but reported earnings showed a $20.95 million loss.